Gyre Therapeutics
GYRE
44 hedge funds and large institutions have $23.6M invested in Gyre Therapeutics in 2025 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 23 increasing their positions, 8 reducing their positions, and 6 closing their positions.
188% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 8
2% more capital invested
Capital invested by funds: $23.1M → $23.6M (+$522K)
0.26% more ownership
Funds ownership: 3.21% → 3.47% (+0.26%)
8% less funds holding
Funds holding: 48 → 44 (-4)
67% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 6
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $85K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$470K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$394K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$375K |
| 4 |
Charles Schwab
San Francisco,
California
|
+$353K |
| 5 |
Morgan Stanley
New York
|
+$351K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$267K |
| 2 |
Lazard Asset Management
New York
|
-$111K |
| 3 |
State of Wisconsin Investment Board
Madison,
Wisconsin
|
-$110K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$103K |
| 5 |
Jane Street
New York
|
-$100K |
GYRE Hedge Fund Activity: Q4 2025 in Review
44 of the 8,270 institutional investors tracked by Wall St. Rank reported a position in Gyre Therapeutics (GYRE) for Q4 2025, worth a combined $23.6M — up 2.3% from $23.1M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of GYRE and 2 opened new positions — a net loss of 4 holders — while 8 trimmed existing stakes and 23 added.
The largest buyer was BlackRock, adding an estimated $470K. The largest seller was Millennium Management, exiting entirely with an estimated $267K sold.
- 44 institutional investors held Gyre Therapeutics (GYRE) as of Q4 2025, down from 48 in Q3 2025.
- Funds reported $23.6M of Gyre Therapeutics stock for Q4 2025, up 2.3% quarter-over-quarter.
- 2 funds opened new Gyre Therapeutics positions in Q4 2025 and 6 closed out, a net change of -4 holders.
- The largest Gyre Therapeutics buyer in Q4 2025 was BlackRock, an estimated $470K added.
- The largest Gyre Therapeutics seller in Q4 2025 was Millennium Management, an estimated $267K sold.
Based on aggregated 13F filings for Q4 2025.